A study of effect of immunity boosting therapy on long-standing ringworm infections
Not Applicable
- Conditions
- Health Condition 1: L089- Local infection of the skin and subcutaneous tissue, unspecified
- Registration Number
- CTRI/2019/10/021656
- Lead Sponsor
- GCS Medical college
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients of either sex, aged more than 18 years ,suffering from chronic and relapsing dermatophytosis,confirmed by positive 10% potassium hydroxide mount for fungal hyphae
Exclusion Criteria
1.Pregnant and lactating females
2.Patients with liver or renal failure or any malignancy
3.Patients with primary or acquired immunodeficiency
4.Patients with any major medical illness or surgical intervention within the preceding 4 weeks
5.Patients on concomitant medications which can interfere with immune response(eg steroids,immunosuppressants,chemotherapeutic agents)
6.Patients with a past history of tuberculosis
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method All the patients in both the groups shall be assessed for <br/ ><br>1Complete Clearance of the dermatophytosis(assessed by Grade of improvement scoring,physicians and patientsglobal assessment score) at the end of 8 weeks <br/ ><br>2)Reduction in the Itch score at the end of 8 weeks <br/ ><br>3)Percentage of patients have having clinical relapse at 4,8,12 weeks after the last Intradermal PPD injection <br/ ><br>Timepoint: 1 Complete clearance of the infection at 8 weeks <br/ ><br> <br/ ><br>2 Absence of relapse at 12 and 20 weeks
- Secondary Outcome Measures
Name Time Method 1)Correlation of serum IgE levels and personal and family history of atopy with the primary outcome measures. <br/ ><br>2)Correlation of preceding topical steroid use with the primary outcome parameters <br/ ><br>3)Correlation of pre-study PPD positivity with the primary outcome measures. <br/ ><br>Timepoint: 8 and 20 weeks